Budget 2026-27: ₹10,000 Crore Biopharma Shakti Program Boosts Pharma Stocks
Finance Minister Nirmala Sitharaman announced the ₹10,000 crore Biopharma Shakti program during Budget 2026-27, spanning 5 years to develop India as a biopharma manufacturing hub. The announcement triggered positive market response with Biocon gaining 3% and other pharma stocks rising 1-2%, reflecting investor confidence in the government's strategic commitment to biologics and biopharmaceutical innovation.

*this image is generated using AI for illustrative purposes only.
Finance Minister Nirmala Sitharaman announced the Biopharma Shakti program with an allocation of ₹10,000 crore during Budget 2026-27 presentation. The announcement triggered immediate positive market reaction among pharmaceutical stocks, with Biocon gaining 3% and other pharma stocks rising 1-2%.
Budget Allocation Framework
FM Sitharaman made the announcement during her ninth consecutive Budget speech on February 1 on the floor of the Lok Sabha. The Biopharma Shakti program represents a strategic government initiative to strengthen India's biopharmaceutical capabilities over the next 5 years.
| Parameter: | Details |
|---|---|
| Total Allocation: | ₹10,000 crore |
| Duration: | 5 years |
| Announcement Date: | February 1 |
| Initiative Name: | Biopharma Shakti |
| Budget Year: | 2026-27 |
Market Response
The announcement generated immediate positive sentiment in the pharmaceutical sector. Market data shows Biocon shares gained 3% following the Budget announcement, while other pharmaceutical stocks recorded gains of 1-2%, reflecting investor confidence in the government's commitment to the biopharma sector.
Government's Strategic Vision
FM Sitharaman emphasized that biologics are key to longevity and outlined the government's plan to develop India as a biopharma manufacturing hub. The initiative will focus on establishing a biopharma-focused network to enhance the sector's infrastructure and capabilities.
The Biopharma Shakti program forms part of the broader Union Budget 2026-27 framework, demonstrating the government's commitment to positioning India as a global leader in biopharmaceutical manufacturing and innovation. This multi-year funding approach provides industry stakeholders with long-term visibility for planning investments and expansion activities.

































